Your browser doesn't support javascript.
loading
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
Pearson, Andrew D J; Rossig, Claudia; Lesa, Giovanni; Diede, Scott J; Weiner, Susan; Anderson, John; Gray, Juliet; Geoerger, Birgit; Minard-Colin, Veronique; Marshall, Lynley V; Smith, Malcolm; Sondel, Paul; Bajars, Marcis; Baldazzi, Claudia; Barry, Elly; Blackman, Sam; Blanc, Patricia; Capdeville, Renaud; Caron, Hubert; Cole, Peter D; Jiménez, Jorge Camarero; Demolis, Pierre; Donoghue, Martha; Elgadi, Mabrouck; Gajewski, Thomas; Galluzzo, Sara; Ilaria, Robert; Jenkner, Alessandro; Karres, Dominik; Kieran, Mark; Ligas, Franca; Lowy, Israel; Meyers, Michael; Oprea, Corina; Peddareddigari, Vijay G R; Sterba, Jaroslav; Stockman, Paul K; Suenaert, Peter; Tabori, Uri; van Tilburg, Cornelis; Yancey, Todd; Weigel, Brenda; Norga, Koenraad; Reaman, Gregory; Vassal, Gilles.
Afiliación
  • Pearson ADJ; ACCELERATE, Europe. Electronic address: andy1pearson@btinternet.com.
  • Rossig C; University Children´s Hospital Muenster, Pediatric Hematology and Oncology, Germany.
  • Lesa G; Paediatric Medicines Office, Product Development Scientific Support Department, European Medicines Agency, Amsterdam, the Netherlands.
  • Diede SJ; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Weiner S; Children's Cause for Cancer Advocacy, USA.
  • Anderson J; UCL Great Ormond Street Institute of Child Health, UK.
  • Gray J; Southampton University NHS Trust, UK.
  • Geoerger B; Gustave Roussy Cancer Centre, France.
  • Minard-Colin V; Gustave Roussy Cancer Centre, France.
  • Marshall LV; Royal Marsden Hospital & Institute of Cancer Research, UK.
  • Smith M; National Institutes of Health, USA.
  • Sondel P; The University of Wisconsin, Madison WI, USA.
  • Bajars M; EMD Serono, USA.
  • Baldazzi C; Tesaro, USA.
  • Barry E; Pfizer, USA.
  • Blackman S; ACCELERATE, Europe.
  • Blanc P; Imagine for Margo, Unite2Cure, France.
  • Capdeville R; Novartis, Switzerland.
  • Caron H; Roche, Switzerland.
  • Cole PD; Rutgers Cancer Institute of New Jersey, USA.
  • Jiménez JC; Agencia Espanola de Medicamentos y Productos Sanitarios and European Medicines Agency, Committee for Medicinal Products for Human Use, Amsterdam, the Netherlands.
  • Demolis P; Agence Nationale de Sécurité du Médicament et des Produits de Santé and European Medicines Agency, Scientific Advice Working Party and Oncology Working Party, Amsterdam, the Netherlands.
  • Donoghue M; Food and Drug Administration, USA.
  • Elgadi M; Boehringer-Ingelheimm Pharma GmbH, Germany.
  • Gajewski T; University of Chicago, USA.
  • Galluzzo S; Agenzia Italiana del Farmaco and European Medicines Agency, Paediatric Committee, Amsterdam, the Netherlands.
  • Ilaria R; Celgene, USA.
  • Jenkner A; Ospedale Pediatrico Bambino Gesù and European Medicines Agency, Paediatric Committee, Amsterdam, the Netherlands.
  • Karres D; Paediatric Medicines Office, Product Development Scientific Support Department, European Medicines Agency, Amsterdam, the Netherlands.
  • Kieran M; BMS, USA.
  • Ligas F; Paediatric Medicines Office, Product Development Scientific Support Department, European Medicines Agency, Amsterdam, the Netherlands.
  • Lowy I; Regeneron, USA.
  • Meyers M; Syndax Pharmaceuticals, USA.
  • Oprea C; Sanofi, France.
  • Peddareddigari VGR; Autolus, UK.
  • Sterba J; University Hospital Brno and European Medicines Agency, Paediatric Committee, Amsterdam, the Netherlands.
  • Stockman PK; AstraZeneca, UK.
  • Suenaert P; Immunicum AB, Sweden.
  • Tabori U; Hospital for Sick Children, Toronto, Canada.
  • van Tilburg C; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.
  • Yancey T; Beigene, China.
  • Weigel B; University of Minnesota, USA.
  • Norga K; Universitair Ziekenhuis Antwerpen, Belgium.
  • Reaman G; Food and Drug Administration, USA.
  • Vassal G; Gustave Roussy Cancer Centre, France.
Eur J Cancer ; 127: 52-66, 2020 03.
Article en En | MEDLINE | ID: mdl-31986450
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Planificación de Atención al Paciente / Evaluación de Necesidades / Desarrollo de Medicamentos / Agencias Gubernamentales / Inmunoterapia / Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Child / Humans Idioma: En Revista: Eur J Cancer Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Planificación de Atención al Paciente / Evaluación de Necesidades / Desarrollo de Medicamentos / Agencias Gubernamentales / Inmunoterapia / Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Child / Humans Idioma: En Revista: Eur J Cancer Año: 2020 Tipo del documento: Article